Phone: 203-315-0566
Fax: 203-315-0565
Website: http://www.marinuspharma.com

Contact(s)
Harry Penner - hpenner@marinuspharma.com

General Information
Marinus is a dynamic specialty pharmaceutical company dedicated to the discovery, development and the commercialization of drugs to treat serious neurological, psychiatric and pain disorders. In 2004, Marinus acquired two exciting development stage compounds. The first, Ganaxolone (licensed from Purdue Pharma), is a Phase II/III product for infantile spasms. The second, MP-0922, is in pre-clinical development for bipolar disorder and schizophrenia. MP-0922 is a repurposed drug that was once a component of a marketed prescription based toothpaste and dental rinse. Both compounds are expected to be in the clinic shortly. Marinus is also pursuing "Phenomenological Drug Discovery" (PDD), an integrated ion vivo drug discovery system. PDD can rapidly generate information on the efficacy and drug-like properties for new chemicals and biologics.

Research Activities
New chemical entities and novel bioassays for epilepsy and depressive disorders. Compounds in early and late preclinical and clinical development.

Other Information
Ownership: Private
CT Employees: 6

Back